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Abstract
Background:  The nucleoside analog, ARC (NSC 188491) is a recently characterized
transcriptional inhibitor that selectively kills cancer cells and has the ability to perturb angiogenesis
in vitro. In this study, the mechanism of action of ARC was further investigated by comparing in vitro
and in vivo activity with other anti-neoplastic purines.
Methods:  Structure-based homology searches were used to identify those compounds with
similarity to ARC. Comparator compounds were then evaluated alongside ARC in the context of
viability, cell cycle and apoptosis assays to establish any similarities. Following this, biological overlap
was explored in detail using gene-expression analysis and kinase inhibition assays.
Results:  Results demonstrated that sangivamycin, an extensively characterized pro-apoptotic
nucleoside isolated from Streptomyces, had identical activity to ARC in terms of 1) cytotoxicity
assays, 2) ability to induce a G2/M block, 3) inhibitory effects on RNA/DNA/protein synthesis, 4)
transcriptomic response to treatment, 5) inhibition of protein kinase C, 6) inhibition of positive
transcription elongation factor b (P-TEFb), 7) inhibition of VEGF secretion, and 8) activity within
hollow fiber assays. Extending ARC activity to PKC inhibition provides a molecular basis for ARC
cancer selectivity and anti-angiogenic effects. Furthermore, functional overlap between ARC and
sangivamycin suggests that development of ARC may benefit from a retrospective of previous
sangivamycin clinical trials. However, ARC was found to be inactive in several xenograft models,
likely a consequence of rapid serum clearance.
Conclusion: Overall, these data expand on the biological properties of ARC but suggest additional
studies are required before it can be considered a clinical trials candidate.
Background
ARC (NSC 188491, SMA-491), 4-amino-6-hydrazino-7-β-
d-ribofuranosyl-7H-pyrrolo-(2,3-d)-pyrimidine-5-car-
boxamide, is a nucleoside analog with profound in vitro
anti-cancer activity. First identified in a high-throughput
screen for inhibitors of p21 mRNA expression, subse-
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quent experiments showed that ARC also repressed
expression of hdm2 and survivin, leading to its classifica-
tion as a global inhibitor of transcription [1].
As an adenosine analog, ARC is related to an important
class of purine anti-neoplastics, including compounds
such as fludarabine, cladribine and clofarabine, used for
the treatment of chronic lymphocytic leukemia, hairy cell
leukemia and refractory acute lymphoblastic leukemia,
respectively [2-4]. Mechanistically, this class of drug
affects quiescent and proliferating cells by impacting DNA
and RNA synthesis. For example, the active metabolite of
fludarabine (F-ara-ATP) competitively inhibits DNA syn-
thesis via DNA polymerase, ribonucleotide reductase,
DNA primase, and DNA ligase whilst also inhibiting RNA
polymerase II [4-6]. Similarly, ARC is thought to act as an
ATP competitive inhibitor of positive transcription elon-
gation factor 2 (pTEF-b), thereby preventing phosphoryla-
tion of RNA polymerase II and blocking transcriptional
elongation [1]. A recent study demonstrated that ARC
inhibits replication of HIV-1 and HCV via pTEF-b, indicat-
ing it may also have utility as an anti-viral therapeutic [7].
However, several observations suggest that ARC has activ-
ities distinct from simple inhibition of transcription. For
example, ARC is considerably more potent than a related
pTEF-b-dependent transcriptional inhibitor, DRB (5,6-
dichloro-1-β-D-ribofuranosylbenzimidazole) in inducing
apoptosis and inhibiting cell viability [1,8,9]. Secondly,
although ARC induces apoptosis in a wide variety of can-
cer cell lines in a p53-independent manner, this effect
appears to be cancer selective, as transformed fibroblasts
and not their 'normal' counterparts are susceptible [1,8,9].
In neuroblastoma cells, ARC was also shown to inhibit the
phosphorylation of Akt at Ser-473, indicating that it may
have additional kinase inhibitory activities [8,9]. Lastly,
ARC was shown to inhibit in vitro angiogenesis assays,
such as endothelial cell cord formation and motility [1].
These observations have driven the continued interest in
ARC as a candidate for clinical development.
In this study, the molecular basis of ARC activity was fur-
ther explored by comparison with related adenosine ana-
logs. Results from structural homology searches identified
sangivamycin and toyocamycin, two cytotoxic nucleo-
sides isolated from Streptomyces, as close relatives [10]. In
a panel of assays, ARC was found to have near identical
activity to sangivamycin, with both compounds capable
of inhibiting pTEFb, protein kinase C (PKC) and VEGF
secretion. The extension of the molecular targets of ARC
from pTEFb to also include PKC provides a mechanism
for ARC cancer selectivity and anti-angiogenic activity in
vitro. However, evaluation of ARC in vivo activity using
several xenograft models yielded disappointing results,
where the lack of tumor response was likely a conse-
quence of short serum half life [11]. These data, combined
with the failure of sangivamycin in clinical trials, suggest
that ARC requires further development (e.g. SAR studies)
before clinical trials should be considered.
Methods
Materials
Compounds including ARC (NSC 188491), sangivamycin
(NSC 143648), toyocamycin (NSC 63701), fludarabine
phosphate (NSC 312887), and 6-thioguanine (NSC 752)
were obtained from the Drug Synthesis and Chemistry
Branch of the Developmental Therapeutics Program,
National Cancer Institute (Rockville, MD). All com-
pounds were prepared at 40 mM in DMSO and stored at -
80°C. All cell lines were from the Division of Cancer
Treatment and Diagnosis (DCTD) Tumor Repository (Fre-
derick, MD). [γ-32P] ATP (specific activity, 3000 Ci/
mmol), [14C] leucine (specific activity, 306 mCi/mmol)
and [5,6-3H] uridine (specific activity, 41 Ci/mmol) were
from Perkin-Elmer (Waltham, MA), and [methyl, 1,2-3H]
thymidine (specific activity, 128 Ci/mmol) was from GE
Healthcare (Piscataway, NJ). Unless indicated in the fol-
lowing methods, all other chemicals were from Sigma (St.
Louis, MO).
Cytotoxicity Assays
Assays were conducted as follows
104 cells in 100 μL were placed into each well of a 96-well
plate 24 h before treatment. Sample or buffer control (10
μL) were added to the appropriate wells and the plates
were incubated at 37°C in a humidified CO2 incubator for
the times indicated in the figure legends. Serum-contain-
ing medium was replaced with serum- and leucine-free
RPMI containing 0.1 mCi of [14C]leucine. Incubation con-
tinued for 2 to 3 h at 37°C. The cells were harvested onto
glass fiber filters using a PHD cell harvester, washed with
water, dried with methanol, and counted. The results are
expressed as % [14C]leucine incorporation into the con-
trol-treated cells. Experiments were done at least twice
with triplicate determinations for each point. The IC50 was
defined as the concentration of adaphostin required to
inhibit protein synthesis by 50% relative to control-
treated cells.
RNA, DNA, and protein synthesis determination
104 cells in 100 μL were placed into each well of a 96-well
plate 24 h before treatment. Sample or buffer control (10
μL) was added to the appropriate wells and the plates
were incubated at 37°C in a humidified CO2 incubator for
the times indicated in the figure legends. At the indicated
times serum-containing medium was replaced with
serum- and leucine-free RPMI containing either 1.3 μCi of
[3H] uridine (RNA synthesis), 1.3 μCi of [3H] thymidine
(DNA synthesis), or 0.03 μCi of [14C] leucine (protein
synthesis). Incubation continued for 2 h at 37°C. TheBMC Cancer 2009, 9:63 http://www.biomedcentral.com/1471-2407/9/63
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cells were harvested onto glass fiber filters using a PHD
harvester, washed with water, dried with methanol, and
counted. Results are expressed as % [3H] uridine, [3H] thy-
midine, or [14C] leucine incorporation into the control
treated cells. Experiments were performed at least twice
with triplicate determinations for each point. Where
applicable, the IC50 was defined as the concentration of
drug required to inhibit protein synthesis by 50% relative
to controls.
Apoptosis and Necrosis Determination
The percentage of apoptotic and necrotic cells in culture
was determined using the Vybrant Apoptosis Assay kit
(Molecular Probes, Eugene, OR) comprising an annexin
VAlexa488 conjugate and propidium iodide as described
by the manufacturer. Acquisition and analysis of data was
performed using a FACScan flow cytometer (Becton-Dick-
inson, Franklin Lakes, NJ) controlled by Cellquest Pro
Software.
Cell Cycle Analysis
Treated cells were harvested and washed once with PBS.
The samples were resuspended in 5 mL PBS and 5 mL cold
70% ethanol were added drop wise. After 5 min incuba-
tion, the cells were centrifuged, resuspended in 10 mL
cold 70% ethanol and stored at 4°C for 1 h. The cells were
washed twice with 5 mL PBS and resuspended in 1 mL
PBS containing 50 μg/mL propidium iodide (Molecular
Probes) and 100 μg/mL RNase A (Sigma). After 1 h at
37°C, cell cycle analysis was performed using the FL3-A
channel on a FACScan flow cytometer.
Western blotting
Cell samples were washed twice with PBS and then lysed
by direct addition of denaturing buffer (5 M urea, 5%
SDS, 0.4 M DTT, 0.002% bromphenol blue and 0.05 M
Tris HCl, pH 8.0). Samples were sonicated, centrifuged for
10 min at top speed in a microfuge, boiled for 5 min and
separated using 10% NUPAGE Bis-Tris gels (Invitrogen,
Carlsbad, CA) with subsequent transfer to a PVDF mem-
brane by electroblotting. Following blocking in 2% blotto
in TBST (Santa Cruz Biotechnology, Santa Cruz, CA) for 2
h, membranes were incubated overnight with either an
anti phospho-(Ser) PKC substrate antibody (1:500 dilu-
tion, Cell Signaling Technology, Danvers, MA) for detec-
tion of total cell protein kinase C substrates containing
phospho-serine, or with an antibody against phospho-
Rpb1 CTD (Ser2/5) (1:1000 dilution, Cell Signaling Tech-
nology) for analysis of phosphorylated RNA polymerase
II. Following overnight incubation, membranes were
washed several times in 2% blotto in TBST, and incubated
with secondary, peroxidase-conjugated antisera for 2 h.
Bands were visualized using the Visualizer Western Blot
Detection Reagent (Upstate, Temecula, CA) according to
the manufacturer's protocol. Imaging was performed
using the Kodak Image Station 2000 MM and Kodak
Molecular Imaging software (Carestream Health, New
Haven, CT).
Reverse Transcription
Total RNA was isolated from cells using the RNeasy mini
kit (Qiagen, Valencia, CA) and reverse transcribed using
Omniscript RT (Qiagen) according to the manufacturer's
instructions. A standard reaction comprised 2 μg total
RNA, 0.5 mM of each DNTP, 2 μM random decamers
(Ambion, Austin, TX) and 4 units of reverse transcriptase
in 20 μL total volume of 1 × RT buffer. The reaction was
allowed to proceed for 120 min at 37°C and the cDNA
product diluted to 1 μg/mL and stored at 80°C.
Real-time RT-PCR
SYBR Green chemistry was used to detect primer specific
amplicons. For each reaction, 12.5 μL Quantitect SYBR
Green PCR mastermix (Qiagen) was diluted 1:2 in DNase
free water containing 5 ng cDNA and 1 μM of specific
primer pair. Reactions were performed in triplicate and
universal 18S RNA primers (Ambion, Austin, TX) were
used to normalize cDNA amplification. The fluorochrome
ROX, included in the PCR mastermix, was used as a pas-
sive reference. Reactions were performed using an
ABI7500 thermocycler (Applied Biosystems, Foster City,
CA). Cycling conditions consisted of a single 10 min at
95°C activation step followed by 40 cycles of 15 s at
95°C, 60 s at 60°C with fluorescence measurements taken
in the elongation step of each cycle. Fold changes in
expression were calculated from ΔΔCt values. For each
primer pair, agarose gel electrophoresis (1%) and melting
curve analysis were used to confirm the presence of a sin-
gle amplicon. The generation of heatmaps from real-time
PCR data was performed using the Genesis software pack-
age (Graz University of Technology, Graz, Austria). Primer
sequences used in QRTPCR provided on request.
PKC and RNA polymerase II phosphorylation
For analysis of the effect of ARC, sangivamycin, toyocamy-
cin, fludarabine or thioguanine on endogenous or TPA-
stimulated protein kinase C activity, logarithmically grow-
ing MCF7 cells were incubated with 100 μM of the drugs
for 9 h. For activation of PKC, 5 μM TPA (Sigma) was
included during the last 2 h of incubation. For analysis of
the effects of the above drugs on RNA polymerase II phos-
phorylation, MCF7 cells were incubated with 100 μM of
the drugs for 3 h. Due to the short exposure times, the 100
μM concentration of drug was selected although it
exceeded the concentration necessary for cell growth inhi-
bition. For both assays, lysates were prepared and immu-
noblotting was carried out as described above.BMC Cancer 2009, 9:63 http://www.biomedcentral.com/1471-2407/9/63
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Kinase assays
The activity of recombinant PKCδ (Upstate) under differ-
ent conditions was determined by measuring the incorpo-
ration of 32P from [γ-32P] ATP into PKC substrate peptide
2 (Millipore, Billerica, MA) according to the manufac-
turer's instructions. PKA activity was determined using the
PKA assay kit (Millipore), which contained purified
recombinant PKA catalytic subunit and the substrate
Kemptide. As a control, the PKA inhibitor peptide (Milli-
pore) was included. The kinase activity of P-TEFb (cdk9/
cyclin T1, Millipore) was determined by measuring the
incorporation of 32P from [γ-32P] ATP into the synthetic
PDK substrate peptide, PDKtide (Millipore), according to
the manufacturer's instructions. For all of the above
kinase assays, 1, 10, or 100 μM ARC, sangivamycin, toyo-
camycin, fludarabine or thioguanine were added to the
reaction tubes for a 10 min preincubation on ice before
initiation of the assay. All assays were performed at least
twice and the data pooled. Results are expressed as a %
activity of control treated cells.
VEGF ELISA
The concentration of VEGF in cell-free culture superna-
tants was determined in triplicates using the Human
VEGF Quantikine ELISA kit (R&D Systems, Minneapolis,
MN) according to the manufacturer's instructions. A
standard curve was generated using recombinant VEGF165
supplied with the kit.
Hollow Fiber Assay
ARC efficacy was first evaluated in vivo using a hollow
fiber animal model [12] in which polyvinylidene fluoride
hollow fibers containing a panel of 12 cancer cell lines in
triplicate were implanted IP and SC into mice as described
previously. The agents, ARC, sangivamycin or toyocamy-
cin, were injected IP daily for 4 days at 2 dose levels. The
doses were selected based upon the single dose maximum
tolerated dose (MTD). From the MTD the highest dose
was calculated as the (MTD × 1.5)/4 and the low dose was
0.67 times the high dose. Twenty-four hours following the
last treatment, the hollow fibers were removed and the
number of viable cells determined using the stable-end-
point MTT assay as described previously [12]. A score of 2
was given for each cell line that had a ≥ 50% reduction in
viable cell mass compared to the control cells. By sum-
ming the scores for all cell lines, doses, and implant sites
a total score was calculated for each test agent. The maxi-
mum total score that can be achieved is 96 (12 cell lines ×
2 sites × 2 doses × 2 points per positive result).
Xenograft models
Human tumor xenograft studies were conducted to assess
the antitumor activity of ARC as described previously
[13]. Briefly, mice were implanted subcutaneously with
MDA-MB-435 (melanoma), NCI-H522 (NSCLC), UACC-
62 (melanoma), or SF-295 (CNS) human tumor cell lines.
Individual tumor growth and body weights were moni-
tored. ARC was administered by the intraperitoneal (i.p.)
and intravenous (i.v.) routes using a dose volume of 0.1
ml/10 gm body weight on each of several dosing sched-
ules. Antitumor efficacy was assessed with several end-
points including optimal % test/control (%T/C), growth
delay and net log cell kill as described previously [14]. In
all animal experiments, animal care procedures were in
accordance with standards described in the National Insti-
tutes of Health Guide for Care and Use of Laboratory Ani-
mals.
Results
Analog selection
Structure-based searches of the PubChem database http:/
/pubchem.ncbi.nlm.nih.gov were conducted to identify
other nucleoside analogues with similarity to ARC. The
SMILES string for ARC was obtained from the Enhanced
NCI Database Browser http://129.43.27.140/ncidb2/ and
searched against the PubChem database set to return any
structure with >90% similarity. This search yielded sangi-
vamycin (NSC 143648) as the primary homology hit
along with several other analogs of this agent. Further
reduction in stringency to 80% expanded the compound
list to include several characterized anti-neoplastic adeno-
sine analogs; including tubercidin (NSC 56408), tricirib-
ine (tricyclic nucleoside, NSC 54020) and toyocamycin
(NSC 63701). Based on results showing high structural
similarity, both sangivamycin and toyocamycin were
selected for side-by-side biological evaluation with ARC.
As controls, the structurally distinct adenosine analog
fludarabine was added along with an unrelated pyrimi-
dine anti-neoplastic 6-thioguanine. Structures for the
compounds utilized in this study are shown in Fig. 1.
Cytotoxicity, apoptosis and cell cycle analysis
ARC was evaluated in the context of 14C-leucine viability
assays using two cell lines, HL60 and MCF7 (Fig. 2). In
both lines, ARC was shown to have activity in the
nanomolar range (Fig. 2A). The maximal effect occurred
within the first 24 h of incubation for HL60 cells, while
for MCF7 cells, the maximal effect did not occur until 3
days of incubation. Expanding this study to a panel of
diverse tumor lines (Fig. 2B) confirmed nanomolar activ-
ity in all cell lines with a 20fold variance at day 1 (IC50
range 20 to 400 nM) which declined to 11fold (4.5 to 50
nM) by day 6 showing that relative cell line susceptibility
gradually disappears with prolonged incubation. Follow-
ing this, HL60 and MCF7 cells were treated with all 5 com-
pounds and IC50  values determined over the same
extended time course (1–6 days) (Fig. 2C). Results dem-
onstrated that in both lines, the time course of cytotoxicity
was similar between ARC, sangivamycin and toyocamy-
cin, and markedly different from fludarabine and thiogua-BMC Cancer 2009, 9:63 http://www.biomedcentral.com/1471-2407/9/63
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nine. Having highlighted general similarities in IC50 for
ARC, sangivamycin and toyocamycin in HL60 and MCF7
cells, the study was then extended to a panel of cell lines
(Fig. 2D). Calculation of correlation coefficients showed
high similarity in activity between ARC and sangivamycin
(correlation coefficient, 0.87), but not between ARC and
toyocamycin (correlation coefficient, 0.25). These experi-
ments suggest for the 5 compounds, ARC and sangivamy-
cin are the closest relatives in terms of growth inhibitory
effects.
Following this, the relative ability of ARC to induce apop-
tosis or perturb the cell cycle was evaluated in HL60 cells.
Results from cell cycle analysis (Fig. 3A) showed marked
increases in the percentage of cells in S and G2M phase
after treatment with ARC, sangivamycin or toyocamycin,
indicating progress towards a G2M block, whereas fludara-
bine demonstrated a partial block in G1 and thioguanine
had little effect. Doxorubicin and cisplatin treated cells
were included as controls and showed the expected S-G2/
M and S phase blocks, respectively. In the context of apop-
tosis induction (Fig. 3A, right panel) ARC, sangivamycin
and toyocamycin produced identical profiles with a small
increase in levels of apoptosis after 48 hr treatment. Thus
ARC, sangivamycin and toyocamycin behave similarly in
these cell-based assays.
RNA, DNA and Protein Synthesis
Given that adenosine analogs are recognized to have glo-
bal effects on DNA and RNA synthesis, the next assays
investigated the relative effects of these compounds on
overall rates of DNA, RNA and protein synthesis (Fig. 3B).
Chemical structures of adenosine, ARC (NSC 188491), sangivamycin (NSC 143648), toyocamycin (NSC 63701), fludarabine  (NSC 312887), and 6-thioguanine (NSC 752) Figure 1
Chemical structures of adenosine, ARC (NSC 188491), sangivamycin (NSC 143648), toyocamycin (NSC 
63701), fludarabine (NSC 312887), and 6-thioguanine (NSC 752).BMC Cancer 2009, 9:63 http://www.biomedcentral.com/1471-2407/9/63
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Results for RNA synthesis showed that, after only 3 h treat-
ment, both ARC and sangivamycin significantly inhibited
RNA synthesis (>40%), whereas the other 3 compounds
had less influence (approximately 15% inhibition). Fol-
lowing 6 h of incubation, ARC, sangivamycin and toyo-
camycin inhibited RNA synthesis by approximately 55–
60%, fludarabine by 25%, while thioguanine had no
effect. For DNA synthesis, the effects of all compounds at
both 3 h and 6 h are less profound than those observed for
RNA synthesis. ARC, sangivamycin and toyocamycin
inhibited DNA synthesis by 5–28% at 3 h and 16–32% at
6 h. Results from protein synthesis showed marked (35–
50%) inhibition with ARC and sangivamycin at 3 h,
increasing to 78–81% at 6 h. At 3 h toyocamycin, fludara-
bine and thioguanine had little effect on protein synthe-
sis, whereas at 6 h toyocamycin inhibited activity by 40%.
Therefore, in terms of DNA, RNA, and protein synthesis,
ARC and sangivamycin have the greatest similarity, influ-
encing RNA and protein synthesis to a greater extent than
DNA synthesis.
The cytotoxic effects of ARC towards cells are similar to that of sangivamycin and toyocamycin Figure 2
The cytotoxic effects of ARC towards cells are similar to that of sangivamycin and toyocamycin. A) Time course 
analysis of ARC on 14C-leucine viability of HL60 cells (upper panel) and MCF7 cells (lower panel). Data from at least 2 replicate 
experiments each with triplicate points were pooled and the SEM are shown when they are greater than the symbol. B) Time 
course analysis of ARC on a panel of 12 cell lines representative of 6 different tumor types. C) Comparison of the cytotoxic 
effects of ARC over 6 days with those of fludarabine (Flud), toyocamycin (TOY), sangivamycin (SAN) and thioguanine (TG) 
towards HL60 (upper panel) and MCF7 (lower panel) cells. The IC50 defined as the concentration of drug required to inhibit 
14C-leucine viability by 50% relative to control treated cells determined from at least two pooled experiments is plotted versus 
time. D) Comparison of activity of ARC with sangivamycin and toyocamycin over a panel of cell lines reveals a high correlation 
coefficient between ARC and sangivamcin. In all panels, cells were incubated with varying concentrations (0.1 – 1000 μM) of 
the indicated drug.BMC Cancer 2009, 9:63 http://www.biomedcentral.com/1471-2407/9/63
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ARC perturbs the cell cycle and induces apoptosis in a similar manner to sangivamycin and toyocamycin Figure 3
ARC perturbs the cell cycle and induces apoptosis in a similar manner to sangivamycin and toyocamycin. (A) 
HL60 cells were incubated with 2 μM of each drug for 48 h and assessed for cell cycle block by flow cytometry using propidium 
iodide (left panel) or for apoptosis using propidium iodide (Y axis) and Annexin V-Alexa488 (X axis) (right panel). (B) ARC and 
sangivamycin have similar effects on RNA, DNA and protein synthesis. Cells were incubated with varying concentrations (1–
10000 nM) of ARC, sangivamycin, toyocamycin, fludarabine and thioguanine for 3 to 24 h. Shown is one of three representative 
experiments depicting the incorporation of [3H] uridine into RNA, [3H] thymidine into DNA and [14C] leucine into protein 
after exposure of MCF7 cells to 1000 nM of the different adenosine analogs for 3 h (upper panel) or 6 h (lower panel) as a % of 
control treated cells.BMC Cancer 2009, 9:63 http://www.biomedcentral.com/1471-2407/9/63
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Inhibition of Protein Kinase C
The parallel activities of ARC and sangivamycin in previ-
ous assays prompted further investigation into whether
ARC treatment reproduces the classical activity of sangi-
vamycin, inhibition of protein kinase C (PKC) [15].
Lysates were prepared from cells treated with 100 μM of
each compound for 9 h in the presence or absence of the
PKC activator, TPA (Fig. 4A). Western blots probed with
an antibody which detects phosphorylated PKC substrates
(anti-phospho-serine PKC substrate) illustrated that the
levels of endogenous phosphorylated PKC substrate
declined significantly after treatment with ARC and sangi-
vamycin in both untreated and TPA exposed cells. Levels
of phosphorylation were unaffected in cells treated with
toyocamycin, fludarabine or thioguanine. We next inves-
tigated the ability of the adenosine analogs to inhibit the
activity of recombinant PKCδ. ARC, sangivamycin and
toyocamycin all inhibited phosphorylation of a PKC sub-
strate peptide in the presence of [γ-32P] ATP (Fig. 4B).
While sangivamycin is reported to be a potent inhibitor of
PKC activity, it has little effect on protein kinase A. In a
similar assay to that used above for PKC, none of the ade-
nosine analogs had any effect on the ability of recom-
binant PKA catalytic subunit to phosphorylate its
respective peptide substrate, Kemptide, whereas the con-
trol PKA inhibitor peptide completely prevented phos-
phorylation (Fig. 4C). Thus, both ARC and sangivamycin
inhibit the kinase activity of PKC, but not of PKA.
Inhibition of P-TEFb-mediated phosphorylation of RNA 
polymerase II
ARC transcriptional repression is thought to occur via
inhibition of P-TEFb-mediated phosphorylation of RNA
Pol II [1]. In order to determine whether sangivamycin
and toyocamycin have similar properties, two assays were
developed measuring either phosphorylation of endog-
enous RNA Pol II, or phosphorylation of the peptide,
PDKtide, by recombinant P-TEFb. Results show that ARC,
ARC and sangivamycin inhibit PKC substrate phosphorylation, PKCδ kinase activity, RNA polymerase II phosphorylation and P- TEFb kinase activity Figure 4
ARC and sangivamycin inhibit PKC substrate phosphorylation, PKCδ kinase activity, RNA polymerase II phos-
phorylation and P-TEFb kinase activity. A) Representative blot of the effects of ARC, sangivamycin, toyocamycin, fludara-
bine and thioguanine on the endogenous PKC activity (upper panel) and TPA-stimulated PKC substrate phosphorylation (lower 
panel). Cells were incubated for 9 h with 100 μM drug. To stimulate PKC, 5 μM TPA was included during the last 2 h of incu-
bation. Lysates were prepared and probed for PKC substrates containing phospho-serine. B) Activity of PKCδ to incorporate 
32P from [γ-32P] ATP into PKC substrate peptide 2 in the presence of the indicated concentrations of drugs. C) Activity of the 
recombinant PKA catalytic subunit to phosphorylate the substrate Kemptide, in the presence of the indicated concentrations 
of drugs and the PKA inhibitor peptide. D) Upper panel, MCF7 cells were incubated with 100 μM ARC, sangivamycin, toyo-
camycin, fludarabine and thioguanine for 3 h before lysates were prepared and probed for phosphorylated RNA polymerase II. 
Lower panel, densitometric analysis of western blots. Data is presented as the total phosphorylated RNA polymerase as a pro-
potion of actin band intensity. E) Purified P-TEFb was incubated with substrate (PDKtide) in the absence or presence of the 
indicated concentrations of drug. The effects of the drugs are presented as % of control.BMC Cancer 2009, 9:63 http://www.biomedcentral.com/1471-2407/9/63
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sangivamycin, toyocamycin and fludarabine inhibit phos-
phorylation of endogenous RNA Pol II (Fig. 4D) while
ARC sangivamycin and toyocamycin prevent recom-
binant P-TEFb from phosphorylating substrate peptide
(Fig. 4E). Thioguanine had no effect in either assay. These
results suggest that inhibition of transcription by ARC,
sangivamycin and toyocamycin is P-TEFb-dependent.
Gene Expression Analysis
Genome wide microarray analysis was performed using
U133 plus 2.0 microarrays (Affymetrix) hybridized to
cDNA from MCF7 cells treated with 2 μM ARC for 24 h
(see Additional file 1). Genes with statistically significant
ARC microarray differentials included those involved in
DNA damage/stress response (example: ATF3, DDIT3,
GADD45A, PPP1R15A, and SESN2), RNA metabolism
(example: EEF2K, ADARB1) and cell cycle regulation
(example: SNF1LK, TP53, CDKN1A). For a subset of dif-
ferentially regulated transcripts, primers were designed to
permit validation by real-time RT-PCR. Cells were treated
with 2 μM ARC, sangivamycin, toyocamycin or fludarab-
ine, and mRNA isolated at a range of time points (4–48
h). Real-time RT-PCR was then performed on all samples
and the results presented in the form of a heat map show-
ing fold change with treatment (Fig. 5). As shown, there is
almost complete concordance between datasets for ARC
and sangivamycin in terms of direction of gene regulation
and the kinetics of change over time. The toyocamycin
profile also has some similarity to ARC, but with what
appears to be a 12–24 h lag phase. For fludarabine, the
profile shows little correlation with ARC, sangivamycin or
toyocamycin in terms of the direction or extent of change.
These data reveal a high degree of similarity between ARC
and sangivamycin in terms of the transcriptomic response
to drug treatment.
Cells treated with ARC or sangivamycin demonstrate almost identical changes in gene expression as determined by Q-RT-PCR Figure 5
Cells treated with ARC or sangivamycin demonstrate almost identical changes in gene expression as deter-
mined by Q-RT-PCR. MCF7 cells were treated with the same dose (2 μM) of ARC, sangivamycin, toyocamycin or fludarab-
ine over a time course (4, 8, 12, 24, 36 or 48 h). Total RNA was then prepared from each sample and reverse transcribed to 
cDNA. Each cDNA sample was then analyzed by Q-RT-PCR to determine changes in mRNA expression for 27 genes involved 
in processes such as the response to cellular stress, DNA damage/repair and apoptosis, that had previously been identified as 
modulated in microaray analysis of ARC treated MCF7 cells. Data is represented in the form of a heat map with limits of 
expression set at +10 fold (red) and -10 fold (green) and the primary results from microarray analysis for the same gene subset 
of MCF7 cells treated with ARC for 24 h shown (column, left).BMC Cancer 2009, 9:63 http://www.biomedcentral.com/1471-2407/9/63
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Inhibition of VEGF secretion
ARC has been shown to possess strong antiangiogenic
activity  in vitro [1]. To compare any inherent antiang-
iogenic potential between drugs, an ELISA-based assay
was used to quantify secretion of vascular endothelial
growth factor (VEGF) from cell supernatants (Fig. 6). Val-
ues of secreted VEGF were calculated as a function of cell
number to correct for the effects of cell death (pg/mL
VEGF/cell). Results demonstrated a 5fold decrease in
VEGF secretion for cells treated with ARC, sangivamycin
or toyocamycin after 24 h. Fludarabine treatment did not
appear to influence secretion whilst thioguanine
decreased VEGF levels by one third. This result confirms
that ARC, sangivamycin and toyocamycin all significantly
inhibit secretion of this important angiogenic factor.
In vivo Activity
ARC was next evaluated in vivo using a hollow fiber assay
and xenograft models. The in vivo doses evaluated for the
ARC, sangivamycin and toyocamycin reflect differences in
the inherent mouse toxicity of each agent (see methods
for dose selection). Interestingly, as reflected in the
administered doses, ARC is almost 50% less toxic acutely
to mice than sangivamycin. In hollow fiber assays, ARC at
75 and 50 mg/kg/injection, had a total score of 54 (IP
score 44; SC score 10) compared to a total score of 50 for
sangivamycin (9 and 6 mg/kg/injection; IP score 42; SC
score 8) and 28 for toyocamycin (0.9 and 0.6 mg/kg/injec-
tion; IP score 26; SC score 2). Total scores of 20 or greater
are considered indicative of potential for evaluation in
xenograft models. Thus, in the hollow fiber assay, ARC
and sangivamycin have similar activity and both are
approximately twice as active as toyocamycin.
ARC, sangivamycin and toyocamycin inhibit VEGF secretion Figure 6
ARC, sangivamycin and toyocamycin inhibit VEGF secretion. MCF7 cells were grown in 6 well dishes to 50% conflu-
ence, washed twice with PBS and 2 mL fresh RPMI-1640 media added. Media was then supplemented with the appropriate drug 
to a final concentration of 8 μM. After 24 h supernatant was removed and any cellular debris depleted by centrifugation. 
Adherent cells were trypsinized and cell numbers determined. An ELISA-based method was used to measure supernatant con-
centrations of VEGF. To avoid changes in cell number negatively influencing levels of VEGF secretion, results are expressed as 
picogram VEGF/mL per cell.BMC Cancer 2009, 9:63 http://www.biomedcentral.com/1471-2407/9/63
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ARC efficacy was then investigated in four xenograft ani-
mal models; 1) H522 non-small cell lung cancer, 2) MDA-
MB-435 melanoma, 3) SF-295 CNS, and 4) UACC-62
melanoma. Treatment was administered i.p. at doses
ranging from 8–100 mg/kg/dose given once or twice per
day for 5–10 days or once every other day for a total of 5
doses. Treatment was administered i.v. at doses ranging
from 32–72 mg/kg/dose given once or twice per day for
5–10 days or once every other day for a total of 5 doses.
Toxicity was noted in the groups receiving 100 or 67 mg/
kg/dose i.p. twice daily for 5 days. ARC did not demon-
strate efficacy against any of the 4 xenograft tumors in 5
separate experiments at any dose, route or schedule eval-
uated. Efficacy was defined as a %T/C value of 40% or less
at any tumor measurement time point [14].
Discussion
ARC (NSC 188491) undoubtedly has profound anti-can-
cer activity in vitro. However, the novelty of this agent
when compared to other adenosine anti-metabolites
remains unclear. Structure-based searches revealed con-
siderable similarity with sangivamycin and toyocamycin,
two extensively studied pyrrolopyrimidine antibiotics
with anti-cancer activity [10,16,17]. Analysis of these
compounds in viability assays against a panel of cell lines
showed a high correlation in cytotoxicity between ARC
and sangivamycin. Both compounds also blocked the cell
cycle in G2/M and had similar inhibitory effects on DNA,
RNA and protein synthesis. For toyocamycin, the correla-
tion with ARC cytotoxicity was less robust and the pattern
of inhibition of RNA, DNA and protein synthesis differed
from that of ARC and sangivamycin. The activity differen-
tial between sangivamycin and toyocamycin has been
described previously [18]. This report inferred that differ-
entials were a consequence of toyocamycin primarily
inhibiting rRNA processing whereas sangivamycin inhib-
ited protein synthesis. Still, the degree of concordance
between ARC and sangivamycin was surprising. Analysis
of transcriptomic changes occurring after treatment with
ARC, sangivamycin or toyocamycin added significance to
the correlation between ARC and sangivamycin given that
these two compounds perturb identical groups of genes
and the slope of change over a time course was almost
superimposable between the two drugs. For toyocamycin,
the presence of a 1224 h lag period in mRNA response
again hints towards functional differences with ARC.
Given results suggesting a correlation between ARC and
sangivamycin, we then speculated as to whether overlap
existed for the molecular targets inhibited by each agent.
The seminal activity of sangivamycin concerns inhibition
of protein kinase C, whereas ARC had been shown to
repress RNA polymerase II activity via P-TEFb [1,19]. In
this regard, a central finding was that ARC is also capable
of inhibiting PKC. This fact provides an alternate molecu-
lar target responsible for ARC anti-cancer activity. PKC
isoenzymes have been suggested as attractive therapeutic
targets for anticancer therapies [20]. Activation of PKC has
been shown to positively affect tumor cell proliferation,
invasion, metastasis, and tumor angiogenesis [21]. If we
assume that PKC is a molecular target for ARC activity
then this may explain the selective ability of ARC to kill
cancer cells, since other PKC inhibitors have also been
shown to have greater activity against cancer cells than
their 'normal' counterparts [22].
Interestingly, in a recent study sangivamycin was shown
to exert differential anti-tumor effects in drug-sensitive
MCF7/wild type (WT) cells and MCF7/Adriamycin
(MCF7/ADR) resistant cells [23]. Wild-type MCF7 cells
were observed to check point in G2/M with sangivamycin
without significant apoptosis, mirroring the HL60 results
obtained here. The cell cycle arrest can be explained in
part by the increase in p53 tumor suppressor protein
thought to be essential for maintaining a G2 arrest [24].
ARC has also been shown to cause an accumulation of
p53, see [1] and Fig 5. For the MCF7/ADR cells sangi-
vamycin also induced an early cell cycle arrest at the G2M
phase but this was followed by massive apoptotic cell
death most likely due in part to expression of inactive p53
protein.
Additionally, both ARC and sangivamycin have anti-ang-
iogenic activity. Sangivamycin has been shown to inhibit
1) growth of human umbilical vein endothelial cells
(HUVEC)  in vitro, 2) cord formation of HUVEC on
matrigel, 3) in vivo formation of new blood vessels in the
chicken chorioallantoic membrane assay and 4) tumor
induced angiogenesis within the mouse dorsal skin
[25,26]. Similarly, ARC inhibits the growth of HUVEC,
cord formation of HUVEC on matrigel and reduces the
motility of HUVEC toward the chemoattractant, VEGF [1].
As shown here, both ARC and sangivamycin inhibit VEGF
secretion. Recently, it has been shown that PKC promotes
the angiogenic activity of HUVEC by enhancing VEGF
expression [27]. PKC inhibitors were shown to inhibit
PMA enhanced cord formation of HUVEC on matrigel
and PMA induced expression of VEGF. Therefore, inhibi-
tion of PKC provides a possible molecular basis for the
anti-angiogenic activity attributed to ARC [1].
The identical behavior of ARC and sangivamycin is inter-
esting given that the latter has been extensively studied in
clinical trials. Several reports exist of Phase I trials of san-
givamycin in patients with a range of malignancies [28-
30]. Likewise, archives of the Developmental Therapeutic
program (DTP) of the NCI contain details of additional
attempts at sangivamycin clinical development (unpub-
lished data). The Eastern Cooperative Oncology Group
treated 47 patients with a total dose ranging from 0.1–2.8BMC Cancer 2009, 9:63 http://www.biomedcentral.com/1471-2407/9/63
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mg sangivamycin/kg and observed no objective or subjec-
tive responses, where the major side effect was hypoten-
sion. The Veterans Administration Chemotherapy Group
treated 15 patients; no therapeutic or toxic side effects
were observed in the first 10 patients treated with 50 mg/
kg/D × 7. The next 2 patients received 100 mg/kg/D × 6 or
10 (total dose of 36 or 60 mg). The higher dose proved
fatal. The last dosage regimen was 150 mg/kg/D × 7,
which proved fatal to the final 3 patients with no tumor
responses observed. Lastly, the New England Medical
Center treated 4 cases of pediatric leukemia. Three of the
four children suffered cardiotoxicity. This led to a review
of the Phase I records in which it was discovered that 2/16
adult patients showed development of A-V conduction
defects. Clinical studies were then halted pending cardiac
toxicity studies in animals. In the feline and canine acute
studies, EKG showed no evidence of cardiotoxicity. Suba-
cute studies using immature canines however, revealed
EKG changes following the second course of sangivamy-
cin administration. Interestingly, tentative support for
potential ARC cardiac toxicity came from Ingenuity Path-
ways IPA-Tox analysis http://www.Ingenuity.com of the
differentially expressed transcript list from ARC treated
cells (results not shown). Here, the spreadsheet of tran-
scripts was imported into ingenuity allowing the software
to automatically determine whether changes in expres-
sion of input genes are associated with a defined toxicity
(for further details see – http://www.ingenuity.com/
library/videos/tox_video/Toxicology_video.htm). Results
showed that cardiac necrosis/cell death was the primary
predicted toxicology for the input list, indicating that ARC
and sangivamycin may have overlapping adverse effects.
As regards in vivo efficacy, ARC was active in hollow fiber
assays but not in several xenograft models. In the hollow
fiber assay, activity was primarily restricted to tumor cells
growing within the peritoneal cavity (i.p. score of 42 vs
s.c. score 10). This is the same physiologic site into which
the test article was injected. Thus, tumor cells were
exposed to high concentrations of ARC immediately post-
injection and systemic bioavailability was not an issue in
this assay. In contrast, administration of ARC (i.p or i.v)
to animals bearing human tumor xenografts requires sys-
temic distribution for antitumor activity to be detected,
thus drug metabolism plays an important role in deter-
mining activity, providing a possible explanation for the
failure of ARC in xenograft studies. Evidence to support
this concept comes from a recent study showing that ARC
is relatively unstable in serum [11]. Therefore, In light of
this pharmacologic data, it appears likely the absence of
antitumor activity resulted from inadequate tumor expo-
sure as a conseqeunce of ARC metabolism.
Conclusion
In conclusion, this study establishes that ARC has identi-
cal in vitro biological activity to the classical PKC inhibitor
sangivamycin. Furthermore, in defining ARC as an inhib-
itor of both PKC and RNA polymerase II mediated tran-
scription through P-TEFb, we provide a molecular basis
for in vitro cancer selectivity and anti-angiogenic activity.
Importantly, although ARC retains some activity in hol-
low fiber assays, the compound was inactive in xenografts.
Pharmacokinetic studies hint that the lack of serum stabil-
ity may be responsible for lack of in vivo activity. It is also
noteworthy that repeated clinical trials of sangivamycin
failed to demonstrate efficacy. Therefore, although in vitro
activity is compelling, additional studies are required
before ARC can be considered for clinical development.
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